Please login to the form below
siltuximab
This page shows the latest siltuximab news and features for those working in and with pharma, biotech and healthcare.
EC approves Janssen rare blood disorder drug
Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... Not every MCD patient will be eligible for treatment with
Latest news
-
FDA approves Janssen drug for rare Castleman’s disease
Sylvant (siltuximab), marketed by Johnson &Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder
-
J&J files rare blood disorder drug siltuximab in US and EU
Johnson &Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder. ... The submissions are based primarily on data from the randomised MCD2001 study, which compared
-
J&J positive about pipeline
Also on the list are fulranumab for osteoarthritis pain; siltuximab for castleman's disease, a rare disorder that is similar to lymphoma; TMC-207 for MDR tuberculosis; TMC 435 for hepatitis
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
-
Account Director, Medical Education
-
Salary TBC
-
Account Executive
-
Salary TBC
-
Account Supervisor
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director
-
Salary TBC
Subscribe to our email news alerts
- The first of many celebrations for Lucid Group at Middlesex House
- FDA advisors say no to empagliflozin in type 1 diabetes
- Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- Novartis makes case for NASH candidate tropifexor
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- RWE Blog 3: Is real-world evidence the holy grail
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- BeiGene bags FDA approval for first product Brukinsa in lymphoma
- Amarin wins FDA advisory nod for Vascepa cardiovascular expansion
- Shionogi scores FDA approval for new cUTI antibiotic
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
- Strengthening business competition and reducing anti-competitive practices
- How the CMA is tackling high prices for essential drugs...
Quick links
Infographics
